

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 37/02</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/00141</b> <b>(43) International Publication Date:</b> 6 January 1994 (06.01.94)
<b>(21) International Application Number:</b> PCT/EP93/01494 <b>(22) International Filing Date:</b> 14 June 1993 (14.06.93) <b>(30) Priority data:</b> MI92A001551 24 June 1992 (24.06.92) IT <b>(71) Applicant (for all designated States except US):</b> BOEHRINGER MANNHEIM ITALIA S.P.A. [IT/IT]; Via S.Uguzzone, 5, I-20126 Milano (IT). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> CAVALLETTI, Ennio [IT/IT]; TOGNELLA, Sergio [IT/IT]; Via S.Uguzzone, 5, I-20126 Milano (IT). <b>(74) Agent:</b> BIANCHETTI, Giuseppe; Studio Consulenza Brevettuale, Via Rossini, 8, I-20122 Milano (IT).		<b>(81) Designated States:</b> AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> GLUTATHIONE AS CHEMOPROTECTIVE AGENT  <b>(57) Abstract</b>  The use of glutathione (GSH) as chemoprotective agent against neurotoxicity induced by antitumor drugs active on the mitotic fuse is herein described.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

### GLUTATHIONE AS CHEMOPROTECTIVE AGENT

The present invention relates to the use of reduced glutathione (GSH) as protecting agent towards neurotoxicity induced by antitumor drugs active on the mitotic fuse.

5        Examples of such drugs include Vinca alkaloids, such as vincristine and vinblastine, and cyclotaxan derivatives, whose parent compound, i.e. taxol, is presently under advanced clinical trial (Anti-Cancer Drugs, 2, 1991, page. 519-530).

10        The most serious limitation to the success of antineoplastic chemotherapy resides in the severe toxicity annexed to the use of antitumor drugs: toxic symptoms limit administrable doses, they affect treatment cycles and seriously jeopardize the life  
15        quality of the oncologic patient.

The high toxicity of the antitumor drugs is due to the lack of selective activity of the drugs themselves, which, besides hitting the tumor cells, interact with other organs or cell populations in the human body.

20        Toxic symptoms deriving from the treatment with antitumor compounds are therefore strictly connected with the chemical structure of the compounds and with their mechanism of action. For example, anthracycline induced cardiotoxicity was strictly related to the  
25        quinone substructure typical of anthracyclines. In fact, this structure undergoes in vivo a single-electron reduction, thus forming the emiquinone radical. This last compound is capable of promoting the avalanche formation of free oxygen radicals, which, in

their turn, are responsible for the cardiac tissue damage. Not by chance several radical scavengers are able to perform a protective effect lowering the anthracycline cardiotoxicity.

5       As another example, cis-platin is an antitumor agent which is endowed with heavy organo-specific toxicities, particularly relevant especially towards kidney. In fact, cis-platin, when absorbed by kidney, forms the diaquo species by loss of two chlorine ions.  
10      This happens since in the renal tubule the concentration of chlorine ions is lower than in blood. So activated cis-platin is capable of damaging the tubules with resulting nephropathy. Several thiol compounds, among which diethyldithiocarbamate and  
15      glutathione are able to protect kidney from the cis-platin effect, since they accumulate at kidney level and probably interact with the compound.

        Cis-platin is known to cause neurotoxic effects too (Eur. J. Cancer Vol. 27(3), 1991, 372-376), which  
20      several protective agents have been evaluated towards; among these, nimodipine (Eur. J. Pharmacol. 1990, 183, 1710-1711) and ACTH (4-9) neuropeptide (Eur. J. Cancer Clin. Oncol. 1988, 89, 81-87) turned out to be the most effective.

25      Also glutathione and other sulphur compounds (thiosulfate, ethiofos, diethyldithiocarbamate) resulted effective to different extents in the prevention of cis-platin neurotoxicity (Tumori, 1987, 73, 337-340, EP-A-0265719 Cancer Res., 1993, 53,  
30      544-549), presumably as an effect coming from the nephrotoxicity protection, which is widely described

especially for glutathione. An uncompromised kidney functional capacity would assure an effective and ready elimination of cis-platin, thus avoiding the accumulation and the resulting toxicity towards other tissues or target cells.

From the whole of the data reported in clinical and pharmacological literature, it comes out that a single agent capable of protecting indiscriminately from the toxic effects of any antitumor compound does not exist. It is neither foreseen that a compound capable of limiting or nullifying the toxicity of a certain antitumor drug can also exert a protecting effect from the toxicity of another antitumor drug belonging to a different chemical class and having a different activity mechanism.

On the other hand, vinca alkaloids and cyclotaxans derivatives, such as taxotere and taxol, characterized by the same cytotoxic mechanisms at microtubule level, share, as unwished side effect, neurotoxicity against peripheral nerve (Neurology, 39, 1980, 368-37; Neuroscience 10(2), 1983, 491-509; J. Neurocytol. 15, 1986, 483 J. Clin. Oncol. 9, 1991, 1261-7). To date, only one study exists about the possibility to fight against vinca alkaloids neurotoxicity by using gangliosides as exogen chemoprotective agents (Cancer Chemother. Pharmacol. 26, 31-36, 1990).

It has now been found that the neuropathy, induced by vinca alkaloids and cyclotaxans derivatives, can significantly be reduced if not totally prevented by means of a pretreatment with reduced glutathione.

This finding comes out to be absolutely surprising

even in the light of the fact that reduced glutathione previously proved to be unable to effectively contrast the neurotoxicity characteristics of other classes of drugs, particularly ototoxicity of the aminoglycoside antibiotics.

According to the invention, reduced glutathione can be administered from about 2 hours to about 15 minutes before administering the antimitotic drug. Reduced glutathione can be administered whether orally or parenterally, in doses ranging from 5 to 500 mg/kg, preferably from 30 to 100 mg/kg. Generally, it has been found that administering from 1 to 5 g of glutathione, preferably 30 minutes before the administration of the antimitotic drug, is capable of giving the most promising results.

Protecting activity is verifiable also when more antitumor drugs are administered at the same time, as in polychemotherapy protocols. In the case where vinca alkaloids and/or taxol or its derivatives are combined, for example, with platinum complexes, such as cis-platin, carboplatin and the like, the previously administered reduced glutathione will exert a global protective effect both on the typical nephrotoxicity of platinum complexes and on the neurotoxicity of alkaloids and taxol or derivatives. Evident therapeutical advantages come out from the present invention, which are particularly significant in the case of bladder, ovary and testicle carcinomas, wherein said combinations are in fact already used or are under evaluation.

Vinca alkaloid and taxol dosages are the only

already described for this kind of drugs, but it can optionally be raised, thanks to the GSH chemoprotective effect, with consequent improvement of the response to the treatment.

5           A preferred embodiment of the invention relates to pharmaceutical compositions consisting of separated administration forms for sequential or separated use containing 1) reduced glutathione and 2) an antitumor drug active on the mitotic fuse. Taxol is particularly  
10 preferred as antitumor drug.

          Typical administration forms comprise lyophilized ampoules to be reconstituted with a suitable sterile solvent (for example saline or glucosated solution), ready-for-use sterile solutions and, optionally, also  
15 capsules, tablets, syrups and other forms suitable to oral administration. In the case of the more common infusion administration, for example, a pharmaceutical formulation containing 1 to 5 g of GSH, preferably 2.5 g, is diluted to a total volume of 50 to 500 ml with  
20 saline and infused within 15 minutes before the administration.

          The present invention is further illustrated, by way of example, by the results from pharmacotoxicological tests using taxol and GSH.

25

#### EXAMPLE

##### Materials and methods

##### Animals and animal care

          The test was carried out in adult male Wistar rats, weighing from 200 to 220 g. The animals were  
30 housed in macrolon cages with free access to feed and water and sawdust as bedding. Each cage housed 4 rats.

Dark-light cycle was 12 hours, with light from 7.30 a.m. to 7.30 p.m..

#### Drugs

5 A stock solution was prepared by dissolving taxol in a suitable solvent. This solution was further diluted with saline immediately before use. GSH was dissolved in distilled water at the concentration of 125 mg/ml.

#### Experimental design

10 Three groups of 8 animals each were subjected to treatment with vehicle + distilled water (age-matched controls), taxol + distilled water, taxol + GSH, respectively. Bodyweight was measured daily and taxol was dosed accordingly. The animals were injected with  
15 taxol 1.2 mg/kg/day (final concentration 0.3 mg/ml) 5 days a week for 7 weeks; during the next 2 weeks a dose of 2.4 mg/kg/day (final concentration 0.6 mg/ml) 5 days a week was administered (cumulative dose: 66 mg/kg). GSH was intravenously administered at the dose of 500  
20 mg/kg 30 min before each taxol injection.

#### Electrophysiology

Electrophysiological determinations were carried out on animals under general anaesthesia with Hypnorm containing 10 mg/ml fluanisone and 20 mg/ml fentanyl  
25 citrate at the dose of 0.8 ml/kg. Sensitive nerve conduction velocity with respect to H reflex (HSNCV) was measured according to the method described by De Koning et al., Neurotoxic side-effects of cisplatin; Eur. J. Cancer, 27: 372-6, (1991). H. Reflex is a long  
30 latency reflex which occurs in response to the stimulation of the sensitive afferent fiber which



monosynaptically excites  $\alpha$ -motoneurons of the spinal cord. HSNCV was calculated dividing the distance between two points of stimulation by the difference between H latencies which were recorded at both sites.

5     Data analysis

Statistical evaluation of the experimental data was performed by an analysis of variance for repeated measurements (ANOVAR) followed by supplemental t tests. The treatment code was opened only after this analysis was completed.

10    Results

General toxicity

During the first 7 weeks (taxol dose 6 mg/kg/week) the taxol treated animals continued to grow almost as fast as the age-matched control. After doubling the dose, however, the animals lost weight and taxol administration had to be discontinued two weeks later, especially as two (out of eight) animals co-treated with saline died during the electrophysiological measurement at the end of this treatment period. During the next 4 weeks no further taxol was administered but two other animals in the taxol/saline group died, one during anesthesia at week 10 and another during the measurement at week 13.

25    Electrophysiology

In the age-matched controls, HSNCV reached normal adult values toward the end of the experiment. A sensory neuropathy, as evidenced by a significant decrease of the HSNCV, developed in the taxol/distilled water treated animals from week 5 onwards. The HSNCV of taxol/GSH treated animals did not significantly differ

from that of the age-matched controls.

The protective effect of GSH against taxol neurotoxicity has also been confirmed by behavioural studies ("tail flick test"), SNCV measurements in the caudal nerve, and morphological and morphometric examination of primary sensitive ganglia and ischiatic and saphenous nerves in rats subjected to: i) "subacute" administration of either 5 or 10 mg/kg/day i.p. of taxol diluted in DMSO for 5 consecutive days; ii) "chronic" administration of either 10 or 20 mg/kg/day i.p. of taxol diluted in DMSO once a week for 5 weeks.

CLAIMS

1. The use of glutathione (GSH) as chemoprotective agent against neurotoxicity induced by antitumor drugs active on the mitotic fuse.  
5
2. The use according to claim 1, wherein antitumor drugs active on the mitotic fuse are selected from vinca alkaloids and cyclotaxans derivatives.
3. The use according to claim 2, wherein antitumor drugs active on the mitotic fuse are selected from vinblastine, vincristine and taxol.  
10
4. The use according to claim 2, wherein taxol is the antitumor drug.
5. Pharmaceutical compositions, consisting of separated administration forms for the sequential or separated use, containing 1) reduced glutathione and 2) an antitumor drug active on the mitotic fuse.  
15
6. Pharmaceutical compositions according to claim 5, wherein taxol is the antitumor drug.
7. Pharmaceutical compositions according to claim 5 or 6, containing a unitary dose of 1 to 5 g of GSH.  
20
8. The use of glutathione (GSH) for the preparation of a medicament for the prevention of neurotoxicity induced by antitumor drugs active on the mitotic fuse.

## INTERNATIONAL SEARCH REPORT

PCT/EP 93/01494

International Application No

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.C1. 5 A61K37/02		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.C1. 5	A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	SEMINARS IN ONCOLOGY vol. 18, no. 1, February 1991, pages 1 - 4 F. M. MUGGIA 'INTRODUCTION: CISPLATIN UPDATE' see page 2	1-6,8
X,Y	EP,A,0 265 719 (BOEHRINGER BIOCHEMIA ROBIN) 4 May 1988 cited in the application see page 3 - page 5; claim 3; examples 1,2 -/--	1-8
<p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search 19 AUGUST 1993		Date of Mailing of this International Search Report 06.09.93
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer KRAUTBAUER B.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	NEUROREPORT vol. 2, no. 6, June 1991, pages 345 - 347 D. I. LEVY 'GLUTATHIONE PREVENTS N-METHYL-D-ASPARTATE RECEPTOR-MEDIATED NEUROTOXICITY' see the whole document ---	1-8
Y	'THE MERCK INDEX, 11TH ED.' 1989, MERCK & CO., INC., RAHWAY, N.J., U.S.A * NO. 9049:"TAXOL", NO. 9887:"VINBLASTINE", NO. 9891:"VINCRIStINE"; * ---	1-8
Y	WO,A,8 602 353 (ZAMBON S.P.A.) 24 April 1986 see page 1 see page 4 - page 5 ---	1-8
Y	WO,A,9 102 810 (THE CHILDREN'S MEDICAL CENTER CORPORATION) 7 March 1991 see page 1 see page 7 see claim 10 -----	1-8

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9301494  
SA 76275

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 19/08/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0265719	04-05-88	AU-B- 605512	17-01-91
		CA-A- 1306693	25-08-92
		JP-A- 63246334	13-10-88
		US-A- 4871528	03-10-89
		ZA-A- 8707502	15-04-88
WO-A-8602353	24-04-86	AU-B- 582600	06-04-89
		AU-A- 5016585	02-05-86
		CA-A- 1262550	31-10-89
		JP-T- 62500871	09-04-87
		US-A- 4761399	02-08-88
WO-A-9102810	07-03-91	EP-A- 0486621	27-05-92

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**